Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Binimetinib (Mektovi) is indicated in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma and non-small cell lung cancer, both specifically with a BRAF V600E or V600K mutation as detected by an FDA-approved test.
• Nine systematic reviews/meta-analyses were reviewed to gather information about Mektovi's efficacy and safety profile.
• The combination therapy of binimetinib and encorafenib shows a superior overall response rate compared to other double and triple therapies such as dabrafenib + trametinib, vemurafenib + cobimetinb for treating metastatic melanoma.
• For patients suffering from metastatic colorectal cancer (mCRC) carrying BRAF V600E mutations, the addition of binimetinib to a regimen including encorafenib significantly improves patient outcomes when compared to conventional therapy.
• Subgroup analyses suggest that younger patients (<55 years) may experience increased risk factors like pulmonary embolism and arterial hypertension due to this drug combo; hence, individual patient factors should be considered.
• Immunotherapies like nivolumab or ipilimumab tend to have better acceptability regarding adverse events than targeted therapies such as MEK inhibitors after 12 months, indicating long-term benefits.